Skip to main content

Advertisement

SpringerLink
Log in

State of the Art HCV Treatment in Children

  • Hepatitis C (H Vargas and S Flamm, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Hepatitis C infection is a global issue with an estimated 5 million children with active HCV infection worldwide. The advent of oral direct-acting antiviral (DAA) regimens has revolutionized treatment in adults with excellent efficacy and tolerability. There are limited data and few approved therapies in children. The aim of this review is to discuss the currently approved regimens for children and the recently reported results of clinical trials of DAA in children.

Recent Findings

DAA regimens are currently approved only for children ≥ 12 years. For most children < 12 years, it is recommended that HCV therapy be deferred until patients are eligible for oral DAA therapies. For treatment-naïve adolescents with HCV genotype 1, 4, 5, or 6, treatment with ledipasvir/sofosbuvir for 12 weeks has been reported to have sustained virologic response at 12 weeks of 98%. For treatment-naïve adolescents with genotype 2 or 3 HCV, sofosbuvir- ribavirin combination therapy (12 weeks for genotype 2 and 24 weeks for genotype 3) has been reported to have SVR12 of 100% and 97%, respectively. There are promising, recently published studies showing excellent SVR12 rates for ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with HCV genotype 1 or 4, and sofosbuvir/daclatasvir in children/adolescents with HCV genotype 4. Finally, ledipasvir/sofosbuvir ± ribavirin for children age 6–12 years with genotypes 1, 3, 4, 5, and 6 treated for either 12 or 24 weeks is reported to have an SVR12 rate of 99%.

Summary

HCV treatment in children is rapidly evolving. There are now highly effective all-oral, interferon-free regimens for children ≥ 12 years. Clinical trials are on-going for adolescents and children < 12 years with a variety of pangenotypic ribavirin-free regimens, with anticipated approvals in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57.

    Article  PubMed  Google Scholar 

  2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–62.

    Article  CAS  PubMed  Google Scholar 

  3. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J. 2011;30:983–5.

    Article  PubMed  Google Scholar 

  4. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000;31:751–5.

    Article  CAS  PubMed  Google Scholar 

  6. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. 2014;59:1411–9.

    Article  CAS  PubMed  Google Scholar 

  7. Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99:4588–91.

    Article  CAS  PubMed  Google Scholar 

  8. Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology. 2004;39:90–6.

    Article  PubMed  Google Scholar 

  9. Matsuoka S, Tatara K, Hayabuchi Y, Taguchi Y, Mori K, Honda H, et al. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics. 1994;94:919.

    CAS  PubMed  Google Scholar 

  10. Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866–70.

    Article  CAS  PubMed  Google Scholar 

  11. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric hepatitis C virus infection. J Infect Dis. 2000;181:419.

    Article  CAS  PubMed  Google Scholar 

  12. Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:168–174.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Matsuoka S, Tatara K, Hayabuchi Y, Nii M, Mori K, Kuroda Y. Post-transfusion chronic hepatitis C in children. J Paediatr Child Health. 1994;30:544–6.

    Article  CAS  PubMed  Google Scholar 

  14. Lee CK, Perez-Atayde AR, Mitchell PD, Raza R, Afhdal NH, Jonas MM. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: The Boston Children’s Hospital Experience. J Pediatr. 2013;163(4):1058–64.

    Article  CAS  PubMed  Google Scholar 

  15. Lee CK, Mitchell PD, Raza R, Harney S, Wiggins SM, Jonas MM. Validation of transient elastography cut points to assess advanced liver fibrosis in children and young adults: The Boston Children’s Hospital Experience. J Peds. 2018;198:84–89.e2. https://doi.org/10.1016/j.jpeds.2018.02.062.

    Article  Google Scholar 

  16. Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology. 2008;47:836–43.

    Article  PubMed  PubMed Central  Google Scholar 

  17. González-Peralta RP, Langham MR Jr, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009;48:630–5.

    Article  PubMed  Google Scholar 

  18. Strickland DK, Riely CA, Patrick CC, Jones-Wallace D, Boyett JM, Waters B, et al. Hepatitis C infection among survivors of childhood cancer. Blood. 2000;95:3065.

    CAS  PubMed  Google Scholar 

  19. •• American Association for the Study of Liver Diseases: HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Available at: https://www.hcvguidelines.org/unique-populations/children. This is the consensus recommendation of the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). They include evidence-based, expert-developed recommendations for hepatitis C management which are updated on a regular basis as new information becomes available.

  20. Jonas MM. Hepatitis C virus infection in children. In: UpToDate Post TW (Ed), UpToDate, Waltham, MA (Accessed on 12/15/2018.) Copyright © 2018 UpToDate, Inc. www.uptodate.com, 2013.

  21. • Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66:371. This study reviews the results of a phase 2, multicenter open-label trial of ledipasvir-sofosbuvir for 12 weeks in adolescents with genotype 1. The regimen was safe, well tolerated and had similar pharmacokinetics to adult reports.–8.

    Article  CAS  PubMed  Google Scholar 

  22. Leung DH, Wirth S, Yao BB, Viani RM, Gonzalez-Peralta RP, Jonas MM, et al. Ombitasvir/partiaprevir/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. Hepatol Commun. 2018;2(11):1311–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, Rizk A, et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47:838–44.

    Article  CAS  PubMed  Google Scholar 

  24. El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, El-Koofy N, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67(5):626–30.

    Article  CAS  PubMed  Google Scholar 

  25. Abdel Ghaffar TY, Naghi SE, Gawad MA, Helmy S, Ghaffar AA, Yousef M, et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis genotype 4. J Viral Hepat. 2018;26:263–70. https://doi.org/10.1111/jvh.13032.

    Article  CAS  PubMed  Google Scholar 

  26. • Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017;66:1102 This study reports the results of combination sofosbuvir and ribavirin treatment for 12 weeks in those with genotype 2 and 24 weeks in genotype 3 patients. The regiment was safe, well tolerated with pharmacokinetics similar to adults.

    Article  CAS  PubMed  Google Scholar 

  27. Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis c in children ages 6-11. Hepatology. 2018;68(6):2158–66.

    Article  CAS  PubMed  Google Scholar 

  28. Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, et al. Pharmacokinetics, safety and efficacy of glecaprevir/pibrentasvir in pediatric patients with genotypes 1-6 chronic HCV infection: part 1 of the DORA study. Hepatology. 2018;68(S1):1347A–8A.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA

    Christine K. Lee & Maureen M. Jonas

Authors
  1. Christine K. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maureen M. Jonas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine K. Lee.

Ethics declarations

Conflict of Interest

Maureen M. Jonas reports grants from Gilead Sciences, grants from AbbVie, grants from Merck, grants from Bristol Myers-Squibb, grants from Roche, and personal fees from Gilead Sciences, outside the submitted work. Christine K. Lee received research support in the form of transient elastography hardware from Echosens; no other support was given.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Hepatitis C

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, C.K., Jonas, M.M. State of the Art HCV Treatment in Children. Curr Hepatology Rep 18, 242–248 (2019). https://doi.org/10.1007/s11901-019-00467-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-019-00467-z

Keywords

Search

Navigation